Cingulate Inc (CING) Straddle

Trading a CING straddle lets you take a pure volatility position on Cingulate Inc without committing to a direction. Cingulate Inc's straddle involves buying (or selling) a call and a put at the same strike and expiration, profiting when the stock moves more (or less) than the combined premium implies. Use our scanner to evaluate CING straddle pricing in real time and find the moments when expected moves are mispriced.

A long straddle on CING profits from large moves in either direction and is a classic play into binary events like earnings, product announcements, or macro releases. A short straddle profits when Cingulate Inc stays range-bound and implied volatility contracts. The breakeven points are simple: strike plus total premium on the upside, strike minus total premium on the downside. Comparing the CING straddle price to historical realized moves helps you judge whether the market is overpaying or underpaying for volatility.

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Earnings, product cycles, macro prints — any time volatility itself is the trade, the CING straddle is the cleanest expression of that view. Our scanner prices every CING straddle against historical realized moves, flags expirations where the market is overpaying or underpaying for vol, and ranks setups by breakeven width and IV rank. Whether you're long a CING straddle into a catalyst or short a CING straddle to harvest decay, the options straddle setups that matter are all in one place.